UK cost agency rejects drugs from AstraZeneca, Bristol and Roche
LONDON (Reuters) - Britain's healthcare cost watchdog NICE said on Friday it was not able to recommend a new diabetes drug from Bristol-Myers Squibb and AstraZeneca, and has asked for more information from the companies.
The National Institute for Health and Clinical Excellence (NICE) has been considering Forxiga, or dapagliflozin, as an add-on therapy for use with other medicines, including insulin.
NICE, which decides if drugs should be paid for on the state health service, also said it had issued draft guidance not recommending Roche's Avastin for ovarian cancer. The agency has already rejected Avastin in other tumor types.
(Reporting by Ben Hirschler; Editing by Elaine Hardcastle)
- Tesla says in talks with BMW over car batteries, parts
- Iran nuclear talks extended seven months after deadline missed
- Exclusive: China ready to cut rates again on fears of deflation - sources
- Actor Dwight Henry eyed in New Orleans killing after arrest for theft
- Some fund managers see oil falling to $60 without OPEC cut